PanGenomic develops a health-tech platform to provide personal control over mental health treatments. The company's mobile app, the Nara App, provides consumers with a knowledge base tailored to an individual's unique user profile, developed by tracking a user's treatment regimen and their specific genomic, proteomics, and microbiome data. Its digital therapeutics clinic platform, the PlantGx Platform, provides health practitioners with access to a consumer's Nara App data. The company was founded in 2015 and is based in Vancouver, Canada.

Cognoa is developing digital products intended to support healthcare providers in expediting diagnosis with the goal of improving access to timely intervention for children and families, starting with autism spectrum disorder (ASD).

We are developing digital diagnostic and therapeutic products with the goal of enabling earlier and more equitable care for behavioral health conditions.

Our mission is to transform the healthcare space with accessible wellness solutions powered by science, and the latest innovations in tech. Through our proprietary apps and platforms, we empower users to take control of their own wellbeing, and overcome long-standing barriers to mental and physical health. We believe that conventional and holistic medicine can (and should) be complementary — and that the key to better long-term outcomes is a holistic, whole-body approach to healing and wellness.

Cognoa seeks to help improve the lives and outcomes of children and their families living with behavioral health conditions. We strive to improve timely, equitable access to a diagnosis for caregivers with early concerns of developmental delay, including autism, to support opportunities for early intervention and improved outcomes for children and their families.